APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON MAY 12, 2022By ApyxMedical|2025-12-12T19:19:07-05:00April 4, 2022|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION WITH CLINICAL STUDY SUPPORT FOR THE USE OF THE RENUVION APR HANDPIECE FOR AESTHETIC PROCEDURES TO IMPROVE APPEARANCE OF LAX SKINBy ApyxMedical|2025-12-12T19:19:32-05:00April 4, 2022|
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2022 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:20:04-05:00March 17, 2022|
APYX MEDICAL CORPORATION NOTIFIED OF PENDING FDA MEDICAL DEVICE SAFETY COMMUNICATION RELATED TO ITS ADVANCED ENERGY PRODUCTSBy ApyxMedical|2025-12-12T19:20:29-05:00March 14, 2022|
APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED PUBLICATION FEATURING RESULTS FROM THE U.S. IDE CLINICAL STUDY EVALUATING THE RENUVION DERMAL HANDPIECE USING APYX’S HELIUM PLASMA TECHNOLOGY FOR DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:27:53-05:00February 17, 2022|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 17, 2022By ApyxMedical|2025-12-12T19:21:22-05:00January 27, 2022|
APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 REVENUE RESULTSBy ApyxMedical|2025-12-12T19:21:47-05:00January 10, 2022|
